4th Feb 2021 12:14
Alliance News) - Amryt Pharma PLC on Thursday said it has signed multi-regional distribution agreements with Medison Pharma Ltd to distribute Juxtapid in Canada, and Lojuxta and Myalept in Israel.
The London-based biopharmaceutical company said Juxtapid is approved for use in the US, Canada and Japan as a supplement to a low-fat diet in sufferers of homozygous familial hypercholesterolaemia, a rare cholesterol disorder. In the European Union, Israel and Brazil, it's known as Lojuxta.
Myalept is also approved in the US and it is a supplement used to help treat leptin deficiency. A deficiency of Leptin may cause obesity.
"Today's announcement is another positive development as we continue to grow our commercial assets in existing and new territories and we further progress towards our goal of becoming a global leader in rare and orphan diseases. We are excited to be working with Medison to leverage their expertise and presence in these territories," said Chief Executive Joe Wiley.
Shares in Amryt Pharma were up 3.4% at 212.00 pence in London on Thursday.
By Zoe Wickens; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
AMYT.L